Evidence map›Paper›PMID 42758281›Full record

ArticleInfectious diseases and therapy2026

Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons.

Sara Y Tartof, Evan J Zasowski, Negar Aliabadi, Gabriella Goodwin, Jeff Slezak, Vennis Hong, Timothy B Frankland, Bradley Ackerson, Qing Liu, Sally Shaw and 11 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06077968 (RETROSPECTIVE STUDY EVALUATING ABRYSVO® VACCINE EFFECTIVENESS AGAINST SEVERE LOWER RESPIRATORY TRACT DISEASE IN OLDER ADULTS), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06077968 active not recruitingnot on this map

Retrospective study evaluating abrysvo® vaccine effectiveness against severe lower respiratory tract disease in older adults

TypeobservationalSponsorPfizerRan2023 to 2029Enrolled1ConditionsRespiratory Syncytial VirusesArmsPrior standard of care receipt of Pfizer's ABRYSVO vaccine
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sara Y TartofDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA. Sara.Y.Tartof@kp.org.ORCID http://orcid.org/0000-0003-2336-8476
Evan J ZasowskiPfizer, Inc., New York, NY, USA.
Negar AliabadiPfizer, Inc., New York, NY, USA.
Gabriella GoodwinDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Jeff SlezakDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Vennis HongDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Timothy B FranklandKaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, HI, USA.
Bradley AckersonSouthern California Permanente Medical Group, Harbor City, CA, USA.
Qing LiuPfizer, Inc., New York, NY, USA.
Sally ShawDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Sabrina WelshPfizer, Inc., New York, NY, USA.
Banshri KapadiaDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Brigitte C SpenceDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Gregg S DavisDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Joseph A LewnardDivision of Epidemiology and Division of Infectious Diseases and Vaccinology, School of Public Health, and Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, CA, USA.
Hina ChowdhryDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.
Michael DutroPfizer, Inc., New York, NY, USA.
Erica ChilsonPfizer, Inc., New York, NY, USA.
Alejandro CanePfizer, Inc., New York, NY, USA.
Kyla HayfordPfizer, Inc., New York, NY, USA.
Elizabeth BegierPfizer, Inc., New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRespiratory syncytial virus (RSV) protein subunit vaccines reduce the risk of severe outcomes such as hospitalization and emergency department (ED) visits for at least two RSV seasons following vaccination. No data have been published on real-world RSV vaccine effectiveness (VE) beyond the second season after vaccination. This study evaluates bivalent RSVpreF VE against RSV-related respiratory disease hospitalizations/ED visits throughout three seasons after vaccination.

methodsThis retrospective test-negative case-control study evaluates bivalent RSVpreF VE among adults aged ≥60 years at Kaiser Permanente Southern California, USA, with lower respiratory tract disease (LRTD) or acute respiratory illness (ARI) over three RSV seasons (11/24/2023-4/18/2026). Cases were RSV-positive without coinfection. Controls were negative for RSV, hMPV, influenza, SARS-CoV-2, and positive for a non-vaccine preventable disease pathogen. Exposure was bivalent RSVpreF (Abrysvo) receipt ≥ 21 days before LRTD/ARI. Adjusted VE was estimated using odds ratios from multivariable logistic regression or generalized estimating equations.

resultsOverall adjusted VE against RSV-related LRTD hospitalization/ED visits was 80% (95% CI 68-87), 70% (95% CI 53-81), and 51% (95% CI -12-78) in the first, second, and third season after vaccination, respectively. Overall adjusted VE against RSV-related ARI hospitalization/ED visits was 81% (71-87), 64% (48-75), and 60% (15-81), respectively. Adjusted VE among non-immunocompromised individuals trended 4-7% higher than corresponding overall estimates. Overall adjusted VE across the three combined seasons was 73% (95% CI 64-80) and 73% (95% CI 65-79) against RSV-related LRTD and ARI, respectively.

conclusionBivalent RSVpreF provides protection against RSV-related respiratory hospitalization/ED visits for at least three seasons after vaccination in this population of older adults with a high prevalence of comorbidities. Estimates in the third season for ARI were more definitive, while those for LRTD were imprecise due to limited event numbers. This suggests bivalent RSVpreF vaccination results in substantial individual and public health benefit.

trial registrationClinicalTrials.gov ID: NCT06077968.

Indexed as

Acute respiratory illnessBivalent RSVpreFHospitalizationLower respiratory tract diseaseRespiratory syncytial virusTest-negativeVaccine effectiveness

Identifiers

PMID42758281

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.